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Abstract
Women with mutations in the breast cancer susceptibility genes, BRCA1 and BRCA2, have
an increased risk of developing breast cancer. Both BRCA1 and BRCA2 are thought to be
tumour suppressor genes since the wild type alleles of these genes are lost in tumours from
heterozygous carriers. Several functions have been proposed for the proteins encoded by
these genes which could explain their roles in tumour suppression. Both BRCA1 and
BRCA2 have been suggested to have a role in transcriptional regulation and several
potential BRCA1 target genes have been identified. The nature of these genes suggests that
loss of BRCA1 could lead to inappropriate proliferation, consistent with the high mitotic
grade of BRCA1-associated tumours. BRCA1 and BRCA2 have also been implicated in DNA
repair and regulation of centrosome number. Loss of either of these functions would be
expected to lead to chromosomal instability, which is observed in BRCA1 and BRCA2-
associated tumours. Taken together, these studies give an insight into the pathogenesis of
BRCA-associated tumours and will inform future therapeutic strategies.
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Introduction
About one in 12 women in the Western world develop
cancer of the breast, and at least 5% of these cases are
thought to result from a hereditary predisposition to the
disease [1,2]. Two breast cancer susceptibility genes in
humans (BRCA1 and BRCA2) have been mapped and
cloned, and mutations in these genes account for most fami-
lies with four or more cases of breast cancer diagnosed
before the age of 60 years. (Note that ‘Brca1’ and ‘Brca2’ are
used in the following discussion to denote the equivalent
genes in mice, and that Roman text indicates the encoded
protein.) Women who inherit loss-of-function mutations in
either of these genes have approximately 85% risk of devel-
oping breast cancer by age 70 years [3]. Both BRCA1 and
BRCA2 are thought to be tumour-suppressor genes, because
the wild-type allele of the gene is observed to be lost in
tumours of heterozygous carriers. As well as breast cancer,
carriers of mutations in these genes are at elevated risk of
cancer of the ovary, prostate and pancreas. Surprisingly,
however, despite the association with inherited predisposi-
tion, somatic disease-causing mutations in BRCA1 or
BRCA2 are extremely rare in sporadic breast cancers [1,2].Breast Cancer Research    Vol 1 No 1 Bertwistle and Ashworth
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The  BRCA1 gene is made up of 22 coding exons and
encodes a protein of 1863 amino acids [4••]. Most of the
coding region shows no sequence similarity to previously
described proteins, apart from the presence of a RING
zinc finger domain at the N-terminus of the protein and
two ‘BRCT’ repeats at the C-terminus [2] (Fig. 1). The
BRCA2 gene has 26 coding exons and encodes a protein of
3418 amino acids, with an estimated molecular weight of
384kDa [2,5••]. The only obvious feature of the BRCA2
protein is the presence of eight copies of a 30–80 amino
acid repeat (the BRC repeat) in the part of the protein
encoded by exon 11 [6•,7•] (Fig. 1). These repeats are able
to bind the RAD51 protein implicated in DNA repair and
recombination [8•,9•].
Functions for the BRCA proteins in both transcriptional
regulation and DNA repair/recombination have been sug-
gested [2]. It is still unclear, however, how loss of BRCA
gene function leads to tumourigenesis. Important clues to
this process are provided by the pathological features of
breast tumours in women who are carriers for mutations in
BRCA1 or BRCA2. These tumours are clearly distinct from
each other, as well as from sporadic tumours [10••]. This
indicates that, despite many similarities in these genes [2],
they must have at least some nonredundant functions.
The evidence for the proposed functions of the BRCA1
and BRCA2 proteins are reviewed and related to some of
the pathological features of BRCA-associated tumours.
Transcriptional regulation
The presence in BRCA1 of a RING finger domain, which
are frequently found in transcriptional regulatory proteins,
led to the tacit assumption that BRCA1 might be involved
in the transcriptional regulation of genes [4••]. Subse-
quently, however, it has become clear that RING finger
domains are found in a wide variety of proteins of differ-
ent function, and are indicative of protein–protein interac-
tion rather than interaction with DNA. Nevertheless,
there is significant accumulating evidence for a role in
transcriptional regulation for BRCA1, and to a lesser
extent for BRCA2. Disregulation of target genes conse-
quent to the loss of BRCA genes is a plausible mechanism
to explain the pathological features of BRCA-associated
tumours. As described below, however, the exact function
of the BRCA proteins in transcriptional regulation is not
yet understood.
A C-terminal fragment of BRCA1, which is fused to the
GAL4 DNA-binding domain, activates transcription of
reporter genes, suggesting that BRCA1 might regulate
transcriptional activation [11•–13•]. The finding that
endogenous, full-length BRCA1 copurifies with the RNA
Pol II holoenzyme complex via an interaction with RNA
helicase A supports such a role for BRCA1 [14•,15,16]. It is
worth noting, however, that RAD51 can also be found in
this complex despite having no known role in transcrip-
tional regulation [17].
Several groups have used overexpression of BRCA1 in
various cell lines to find targets of BRCA1 transcriptional
regulation (Table 1). Most work has concentrated on the
cell division kinase (CDK) inhibitor, p21WAF1, which acts
to arrest the cell cycle at the G1 to S phase and G2 to M
phase transitions [18]. In COS cells, 293T cells and human
colon cancer cells, reporter constructs containing portions
of the p21WAF1 promoter are activated by overexpression of
Figure 1
Features of the BRCA1 and BRCA2 proteins.
Structures, features and regions of interaction with
other proteins discussed in this review are indicated.
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BRCA1 [19•,20–22]. Furthermore, in colon cancer cells,
BRCA1 overexpression leads to an increase in p21WAF1
protein levels, accompanied by cell cycle arrest [19•].
There may be some cell-type specificity in this, however,
because overexpression of BRCA1 in osteosarcoma cells
does not induce increased p21WAF1 protein levels [23•].
Other studies suggest that BRCA1 may also be able to
activate the promoters of the proapoptotic gene BAX, the
G2 to M phase checkpoint gene GADD45, and the p53 reg-
ulatory gene MDM2 [20,21,23•].
There are also some indications that BRCA1 may act as a
repressor of transcription. BRCA1 overexpression has
been shown to inhibit transcription from the promoter of
the cell-cycle regulatory gene CDC25A and from a syn-
thetic oestrogen receptor-responsive promoter [24,25•].
This may involve the interaction of BRCA1, via CtIP,
with the transcriptional corepressor CtBP [26•,27•]. CtBP
can inhibit transcription by binding the histone deactylase
HDAC1, which has been found in BRCA1-containing
complexes [28•]. When BRCA1 alone is overexpressed in
293 cells, a p21WAF1 promoter–reporter construct is acti-
vated, but when CtIP and CtBP are coexpressed it is not
[27•]. Interestingly, interaction of BRCA1 with CtIP and
CtBP is disrupted upon DNA damage, suggesting a role
for BRCA1 in the DNA damage-dependent induction of
p21WAF1 [27•]. Because loss of Brca1 in mouse embryos
also leads to induction of p21WAF1 [29••], however, the role
of BRCA1 in p21WAF1 regulation is not clear.
There are, as yet, no reports of BRCA1 binding DNA and
acting directly as a transcription factor. Rather, BRCA1
appears to exert its influence on transcription as a cofactor
or adaptor, because it can interact with both DNA-binding
transcription factors and the RNA Pol II holoenzyme. The
influence of BRCA1 on the p21WAF1, BAX and MDM2 pro-
moters is mediated, at least in part, by p53, with which
BRCA1 has been shown to physically interact [20–22].
Transcriptional regulation has also been proposed as a
function of BRCA2, because sequences encoded by exon
three, when fused to the GAL4 DNA-binding domain,
can activate transcription of a reporter gene [30•]. It is not
clear whether these sequences can function similarly in
the context of the intact protein, however. Other evidence
supporting a role for BRCA2 in transcriptional regulation
is that it can associate with histone acetyltransferase
(HAT) activity. The exact nature of this association is not
clear, because one study suggested that BRCA2 has intrin-
sic HAT activity [31•], whereas another suggested that it
is associated with HAT activity by virtue of an interaction
with P/CAF, which possesses HAT activity [32•]. Associa-
tion with HAT activity does not necessarily denote a role
in transcriptional regulation, however. It could also reflect
a role in chromatin remodelling, which might be required
for the proposed role of BRCA2 in homologous recombi-
nation, which is discussed below.
The promoters that BRCA1 has been shown to activate
are those for stress-induced genes involved in cell cycle
checkpoints, whereas those that BRCA1 inhibits are for
cell division promoting genes. This is consistent with
BRCA1 regulating checkpoints and cell proliferation. Par-
ticularly interesting in this context is the report that over-
expression of BRCA1 can inhibit oestrogen receptor
signalling [25•]. This suggests a model whereby loss of
BRCA1 could lead to an increased proliferative capacity of
the breast epithelium in response to oestrogen. However,
this appears to be at odds with clinical findings that show
loss of the oestrogen receptor in a high proportion of
BRCA-associated breast tumours [33,34].
A major problem with many of the studies described
above is that overexpression of BRCA1 itself, especially at
inappropriate phases of the cell cycle, could cause geno-
toxic stress and thus lead to expression of stress-induced
genes as a secondary effect. Experiments using BRCA-null
cells in which exogenous BRCA expression is induced to
wild-type levels at the appropriate time in the cell cycle
would rule out this possibility.
DNA repair
Mouse cells with Brca1 or Brca2 mutations are hypersensi-
tive to ionizing radiation, a genotoxic treatment that
causes primarily double-strand breaks in DNA [35••–38••].
This suggests that Brca1 and Brca2 play a part in the cellu-
lar response to DNA double-strand breaks. This function
may be restricted to part of the cell cycle, however,
because Brca2 mutant cells can repair the double-strand
breaks that arise during V(D)J recombination [38••]
(Bertwistle D, Ashworth A, unpublished observations);
these occur during the G1 phase of the cell cycle, when
nonhomologous end joining (NHEJ) is thought to repair
most double-strand breaks [39]. Expression of BRCA1 and
BRCA2 is very low during G1 phase, but is induced as
Table 1
Suggested transcriptional targets of BRCA1
Gene Regulation Function
p21WAF1 ­¯* inhibitor of cyclin dependant kinases
BAX ­ proapoptotic
GADD45 ­ G2/M checkpoint
MDM2 ­ regulation of p53
CDC25A ¯ phosphatase/cell cycle regulation
Synthetic estogen ¯
receptor responsive promoter
*Overexpression of BRCA1 activates p21WAF1 expression
[19•,20–22]. However, p21WAF1 is also activated in BRCA1-null mice
[29••].cells enter S phase [40•,41•]. During the late S and G2
phases of the cell cycle, when there are two copies of chro-
mosomes, one copy can be used as a template to repair
double-strand breaks in the other by homologous recom-
bination [39]. In dividing mammalian cells as many as
30–50% of DNA double-strand breaks may be repaired
this way [42]. RAD51, a protein that plays a key role in
homologous recombination, has been shown to associate
with both BRCA1 and BRCA2 [8•,9•,35••,43,44••]. Fur-
thermore, BRCA1 also associates with the
RAD50–MRE11–nibrin complex, which is thought to
process DNA double-strand breaks for repair by both
NHEJ and homologous recombination [45••]. Together,
these data suggest that BRCA1 and BRCA2 are involved
in homologous recombination-mediated repair of DNA
double-strand breaks. To complicate matters, however,
there is also some evidence that BRCA1 may have a role
in the mechanistically independent process of the tran-
scription-coupled repair of oxidative DNA damage [46].
Spontaneous chromosomal abnormalities are observed at
high frequency in untreated Brca1 and Brca2 mutant cells,
implying that these genes act to repair DNA damage that
occurs as a consequence of normal cell division, as well as
that caused by genotoxic agents [36••,38••]. The nature of
the chromosomal aberrations suggests a defect in the
repair of DNA damage sustained during the S or G2 phase
of the cell cycle. Because BRCA1 and BRCA2 are associ-
ated with RAD51, it is significant that loss of RAD51
causes chicken DT40 cells to spontaneously accumulate
DNA double-strand breaks, arrest at the G2/M phase tran-
sition and die [47]. A possible explanation for such severe
phenotypes comes from studies in bacteria, which suggest
that double-strand breaks occur frequently as a normal
consequence of DNA replication and are repaired by
homologous recombination [48]. The role of homologous
recombination in DNA replication in eukaryotes is less
clear. Holliday junction recombination intermediates do
spontaneously arise in normal yeast cells during S phase,
however [49]. This suggests that homologous recombina-
tion repairs DNA damage that occurs spontaneously
during DNA replication in eukaryotic as well as in
prokaryotic cells. The embryonic lethality observed in
Rad51 null mice [50] and many Brca1 and Brca2 mutant
mouse strains may therefore be due to a failure of DNA
replication.
Cell cycle checkpoint activation and loss
Cells respond to DNA damage by activating checkpoints
that prevent their progression through the cell cycle. The
spontaneous DNA damage observed in Brca1 and Brca2
mutant cells would be predicted to activate such check-
points. Indeed, these cells suffer from a proliferative
defect, probably due to checkpoint activation caused by
upregulation of the CDK inhibitor p21WAF1 [29••,37••,
38••]. P21WAF1 is induced in response to DNA damage by
p53, which is upregulated in Brca2 mutant cells. There-
fore, loss of the p53 pathway would be predicted to allevi-
ate the proliferation defect observed in Brca1 and Brca2
mutant cells. Although this may be the case for some muta-
tions [51••], others are only partially rescued [52••] (Connor
F, Ashworth A, unpublished observation), suggesting that
this is not the only checkpoint that is activated. Neverthe-
less, loss of the p53 pathway appears to be important for
the progression of BRCA-associated tumours. Supporting
this hypothesis is the finding that p53 mutations are found
at a higher frequency in BRCA-associated breast tumours
than in sporadic breast tumours [53••,54••].
Checkpoints exist at G1/S, S, G2/M and M in the cell
cycle, and all these appear to be operational in Brca2
mutant cells [38••,51••]. In contrast, cells in which exon 11
of Brca1 is deleted have an intact G1/S checkpoint, but are
defective in an ionizing radiation-induced G2/M check-
point [55••]. Furthermore, cells overexpressing a C-termi-
nal fragment of BRCA1 fail to arrest when treated with the
spindle inhibitor colchicine [56]. These results suggest
that BRCA1 may also be involved in the G2/M and spindle
checkpoints.
The spindle checkpoint acts to monitor the fidelity of
chromosome segregation during mitosis [57]. Chromo-
some segregation is controlled by the mitotic spindle, a
system of microtubules organized by the centrosome.
During mitosis, there are two centrosomes, one at either
end of the mitotic spindle, and one diploid set of chromo-
somes segregates to each. The spindle checkpoint pre-
vents chromosome missegregation by ensuring that each
chromosome pair has recruited microtubules from both
poles of a bipolar spindle, before chromosome segregation
occurs at anaphase.
At the end of mitosis each daughter cell inherits one of the
two centrosomes, and duplicates this at the G1/S phase tran-
sition so that it has two centrosomes during mitosis [58].
Recent studies have found that a high proportion of Brca1
and Brca2 mutant cells contain supernumerary centrosomes
[55••,59••]. There is thought to be no checkpoint monitor-
ing the number of centrosomes in a cell, and therefore cells
with excess centrosomes can enter mitosis [60]. Some of
these cells might be predicted to arrest during mitosis due
to the activation of the spindle checkpoint, however.
Indeed, the growth of Brca2 mutant cells can be rescued by
the expression of a dominant negative mutant of the
spindle checkpoint gene BUB1 [51••]. This implies that
some  Brca2 mutant cells activate the spindle checkpoint.
Under certain circumstances, however, mitoses with super-
numerary centrosomes can fail to activate the spindle
checkpoint [60] and this could lead to chromosome misseg-
regation [61]. The consequence of this would be chromo-
some gain or loss and therefore aneuploidy, which is
Breast Cancer Research    Vol 1 No 1 Bertwistle and Ashworth
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cells [55••,59••]. These results suggest that Brca1 and
Brca2 may regulate centrosome duplication. The finding
that BRCA1 associates with centrosomal proteins supports
this hypothesis [62]. Alternatively, the excess of centro-
somes in Brca1 and Brca2 mutant cells may be a secondary
effect; centrosomes can undergo multiple rounds of dupli-
cation during S-phase arrest leading to supernumerary cen-
trosomes [60,63]. Whatever the mechanism of centrosome
amplification in Brca1 and Brca2 mutant cells, this phe-
nomenon suggests that mutations in BRCA1 and BRCA2
might cause chromosomal instability in human tumours. It
will be interesting to know whether these tumours have a
high frequency of mutations in spindle checkpoint genes.
The chromosomal aberrations and aneuploidy found in
mouse cells mutant for Brca1 or Brca2 are in agreement
with the pathological data showing chromosomal instabil-
ity in BRCA-associated breast tumours [64•]. In the light of
these profound and irreversible changes, therapeutic
strategies involving the reintroduction of BRCA1 or
BRCA2 into tumours [65] may well be viewed as closing
the stable door after the horse has bolted.
Conclusion
Our understanding of the precise functions of the BRCA1
and BRCA2 proteins and how their loss leads to tumouri-
genesis is still incomplete. However, we now have several
clues as to the general cellular processes in which these
proteins are involved, and this understanding has already
illuminated some of the pathological features of BRCA-
associated breast tumours. Activation or repression of tran-
scriptional targets of the BRCA1 protein might play a role
in tumour initiation or progression. These changes in gene
expression may underpin some of the pathological changes
associated with the tumours. Lack of activation of stress-
induced checkpoint genes could contribute to aneuploidy.
Failure to inhibit growth promoting genes could increase
and disregulate proliferation. The genetic instability
observed in mouse models and human tumours most likely
reflects a role for BRCA1 and BRCA2 in homologous
recombination and possibly in centrosome regulation. This
effect may manifest itself relatively early in breast cancer
progression, increasing the probability of tumourigenesis
rather than directly promoting tumour growth. The
synergy between mutations in p53 and the BRCA genes in
tumours indicates a role for loss of checkpoint control in
tumour progression. Taken together these findings give an
insight into the pathogenesis of BRCA-associated tumours
and will inform future therapeutic strategies.
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